FAP and neoplasm: However, accumulating evidence has demonstrated that the use of anti-fibrotic drugs [75] or molecules targeting CAF-derived pro-tumor factors, including TGF-β receptor-I/ALK5 inhibitors or TGF-β-neutralizing antibodies [76], inhibitors of IL-6 [77], recombinant fusion protein directed against FAP (such as RO6874281) [78] or nanovaccines targeting FAP [79], exerts a strong anti-tumor activity in several solid tumors [41].